Development and Characterization of Nanofiber Strip Containing Sertraline for Buccal Application

Creative Commons License

Özcan K., Saral Acarca E. S., İLBASMIŞ TAMER S.

Fabad Journal of Pharmaceutical Sciences, cilt.48, sa.3, ss.385-394, 2023 (Scopus, TRDizin)

Özet

Sertraline is one of the selective serotonin reuptake inhibitors indicated in major depressive disorder. Schizophrenia is a mental disorder with frequent depressive symptoms. Sertraline is thought to be useful for the treatment of depressive symptoms in schizophrenia. The objective of this study is to formulate sertraline-containing nanofiber strips produced by the electrospinning process, that can be easily dispersed by the buccal route, suitable for the use of schizophrenia patients. Here, various ratios (5%,7.5%, and 10%) of polyvinyl pyrrolidone (PVP) polymer solutions were prepared, and electrical conductivity, viscosity, and surface tension characterization studies were performed on polymer solutions. After characterization studies, a polymer solution containing 5% PVP was selected to prepare nanofibers. Nanofibers were obtained using the electrospinning method, each strip containing 5 mg sertraline. It was observed that the chosen optimum formulation nanofiber had an average particle diameter of 371-439 nm in the SEM image. Tensile strength and elongation at break percentage values of 5% PVP-sertraline nanofibers values were 0.449±0.284 (Mpa) and 22.6±3.66 (%), respectively. The loading capacity and encapsulation efficiency of the formulation are 4.53±0.31% and 79.61±10.56%, respectively. In vitro drug dissolution studies showed that sertraline-containing buccal nanofibers conformed to the Hixson-Crowell kinetic model.